In lung cancer, miR-133b is significantly decreased, and it acts as a tumor repressor to inhibit lung cancer development by inhibiting the SRY-box transcription factor 9 (SOX9)/b-catenin signaling pathway [13]. Here, SOX9 is linked to neoplasm.